All In Biotech

Drug Trial Radar · NCT02998450

A Study of IMR-687 in Healthy Adult Volunteers

A Phase 1a Study of IMR-687 in Healthy Adult Volunteers

Last checked: Nov 20, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

66

Actual

Start

Oct 18, 2016

Primary completion

Jul 8, 2017

Study completion Jul 8, 2017

Sponsor

Sponsor type
Industry
Collaborators
Quintiles, Inc.; Imara, Inc.
First posted
Dec 20, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this Phase 1a, first in human, randomized, double-blind, placebo-controlled study is to evaluate the safety, tolerability, PK and PD profile of the orally administered IMR-687 in healthy adult subjects.

Conditions

  • Sickle Cell Disease
  • Sickle-Cell; Hb-SC
  • Sickle Beta 0 Thalassemia

Interventions

  • IMR-687Drug

    1 of 6 possible single doses administered orally following overnight fast

  • Placebo Oral CapsuleDrug

    Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with treatment emergent adverse events and serious adverse eventsTime frame: 5 Days
  2. Number of participants with clinically significant changes from baseline in vital signsTime frame: Baseline to Day 5
  3. Number of participants with clinically significant changes from baseline in physical examinationTime frame: Baseline to Day 5
  4. Number of participants with clinically significant changes from baseline in hematology, chemistry, coagulation and urinalysis laboratory valuesTime frame: Baseline to Day 5
  5. Number of participants with clinically significant changes from baseline in 12-lead ECG parametersTime frame: Baseline to Day 2
  6. Use of concomitant medications and therapies, medication type and frequencyTime frame: 5 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Quintiles

    Overland Park, Kansas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.